Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hyperglycemic clamp Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Glucagon on Hepatic Metabolism

NCT05500586
View directory record Official record
Conditions
Obesity, Type2diabetes, NAFLD
Interventions
Glucagon response study
Drug
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 2:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of β Cell Dysfunction in Relatives of Individuals With Type 1 Diabetes Mellitus

NCT04362917
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
There is no intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus

NCT00829699
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
euinsulinemic euglycemic glucose clamp, euinsulinemic hyperglycemic glucose clamp, Hyperinsulinemic euglycemic glucose clamp, Hyperinsulinemic hyperglycemic glucose clamp
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 16, 2026, 2:41 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

NCT07224334
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 16, 2026, 2:41 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man

NCT02518932
View directory record Official record
Conditions
Insulin Resistance
Interventions
Last 5 amino acids of GLP-1, placebo saline
Drug
Lead sponsor
Elahi, Dariush, PhD
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 16, 2026, 2:41 PM EDT
Not listed No phase listed Observational

Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant

NCT03415139
View directory record Official record
Conditions
Diabetes Mellitus, Cancer
Interventions
Oral Glucose Tolerance Test (OGTT), 2 OGTTs with and without GLP-1 analogue, Hyperglycemic clamp procedure
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Glucose Metabolism in the Immediate and Short Term Follow up After Bariatric Surgery

NCT00488423
View directory record Official record
Conditions
Diabetes, Gastric Bypass
Interventions
Mixed Meal Tolerance test, Hyperglycemic clamp
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
19 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

NCT04459338
View directory record Official record
Conditions
Healthy
Interventions
Exendin-9,39, Saline
Biological · Other
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 16, 2026, 2:41 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

NCT06972407
View directory record Official record
Conditions
Genetic Predisposition, Type2diabetes
Interventions
Exendin 9-39, Saline
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Type 2 Diabetes and the Brain in Adolescents

NCT03461510
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity, Pediatric Obesity, Insulin Resistance, Dysglycemia, Hyperglycemia
Interventions
Hyperglycemic clamp, Hyperinsulinemic Euglycemic clamp
Procedure
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 16, 2026, 2:41 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery

NCT07212868
View directory record Official record
Conditions
Non-Diabetic
Interventions
REMD-477 versus Placebo, Exogenous glucagon versus saline infusion
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 16, 2026, 2:41 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

NCT01803451
View directory record Official record
Conditions
Post-bariatric Surgery
Interventions
exendin -(9-39)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects

NCT02053935
View directory record Official record
Conditions
Hyperglycemia, Sepsis
Interventions
Dopamine
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)

NCT02580604
View directory record Official record
Conditions
Osteoporosis
Interventions
Calcium Chloride/Calcium Gluconate, Half-Normal Saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 80 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Insulin Secretion in Diabetes Before and After Glycemic Control

NCT00469833
View directory record Official record
Conditions
Diabetes, Hyperglycemia
Interventions
insulin glargine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
30 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 16, 2026, 2:41 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome

NCT03520153
View directory record Official record
Conditions
McCune-Albright Syndrome, Fibrous Dysplasia, Intraductal Papillary Mucinous Neoplasm, Diabetes Mellitus
Interventions
Hyperinsulinemic Euglycemic Clamp and 2H20, Hyperglycemic Clamp, Oral Glucose Tolerance Test
Procedure · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Incretin Action in Physiology and Diabetes

NCT02550548
View directory record Official record
Conditions
Insulin Secretion
Interventions
GIP infusion, GLP-1 infusion, Ex-9 infusion
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 16, 2026, 2:41 PM EDT
Not yet recruiting Not applicable Interventional

Using Wearable Sensors To Understand Low Blood Sugar in Type 1 Diabetes

NCT06727071
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hyperglycemic clamp
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 16, 2026, 2:41 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Alpelisib Challenge Test (ACT)

NCT07778524
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants
Interventions
Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 16, 2026, 2:41 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Regulation of Insulin Secretion by the GLP-1 Receptor

NCT02844907
View directory record Official record
Conditions
Insulin Secretion
Interventions
Exendin (9-39), Dexamethasone, Hyperglycemic Clamp
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 16, 2026, 2:41 PM EDT
Terminated Phase 4 Interventional Results available

Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis

NCT01409993
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Sildenafil, Placebo, Hyperglycemic clamp, Euglycemic clamp
Drug · Diagnostic Test
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 16, 2026, 2:41 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp

NCT05456854
View directory record Official record
Conditions
Metabolic Disease
Interventions
Hyperglycemic Clamp, Kisspeptin-10, Placebo
Diagnostic Test · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 16, 2026, 2:41 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion

NCT03998709
View directory record Official record
Conditions
Healthy
Interventions
Somatostatin, Dextrose, Insulin, Intralipid
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 1

NCT00574665
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Hyperinsulinemic Hyperglycemic Clamp
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 16, 2026, 2:41 PM EDT